The unofficial ecosystem briefing for SNMMI 2026.
The radiopharmaceutical and molecular imaging field is moving faster than the program book can keep up with. This is the read of the floor, the program, and the plays that matter, built by Bracken.
May 30 to June 2, 2026 · Los Angeles Convention Center
Colin G. Miller, PhD, FIPEM, CSci
Co-founder and CEO of The Bracken Group. Thirty plus years in medical imaging in clinical trials, with deep work in nuclear cardiology, oncology imaging, and theranostics.
Bracken's CEO will be on the floor at SNMMI 2026; specific session and booth details to be confirmed.
All 248 exhibitors, indexed by capability
Find the booths that matter, with two Bracken-built lenses for theranostics and imaging endpoints.
Browse exhibitors →The radiopharma value chain in one view
From isotope supply to imaging endpoints, see how the floor breaks down and where the bottlenecks sit.
Open the map →The State of Radiopharma 2026
Bracken's read on theranostics, supply chain, the CDMO build-out, AI, and what to watch in the next 24 months.
Read the report →The radiopharma decade arrived faster than the floor plan suggests.
What looked like a niche corner of nuclear medicine three years ago is now driving capital flows, manufacturing strategy, and clinical trial design across oncology. SNMMI 2026 is the room where you can read that shift in one walk.
Our briefing is built to help you read it faster: the exhibitors that matter, the sessions to block, and the questions worth asking out loud.
Read the State of Radiopharma 2026 →Get the SNMMI briefing in your inbox.
One email before the show with our exhibitor lenses and session picks. One after with what actually mattered.